Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Optimal Heart Failure Therapy in accordance with European and National Guidelines~* LVEF ≤ 0.40~* eGFR \> 30 ml/min/1.73 m2~* BMI \< 45 kg/m2~* NYHA class I-III~* Age \> 18 years~* If T2D - optimal treatment in accordance with European and National Guidelines~* If T2D - stable doses of antiglycemic treatment for 30 days~* If T2D - HbA1C 6.5-10%~Exclusion Criteria:~* CRT-D/-P implanted \< 90 days~* Uncorrected severe valvular disease~* Non-compliance~* Use of metalozone~* NYHA IV~* Age \> 85 years~* Dementia~* Admission for HF \< 30 days~* Admission for hypoglycemia \< 12 month~* Known sustained VT~* Symptomatic hypotension and systolic BP \< 95 mmHg~* Unable to perform an exercise test~* Immobilization~* Pregnancy~* Participation in other medical trials~* Previous intolerance of Empagliflozin or excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin 10 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).